<code id='9A21B44C83'></code><style id='9A21B44C83'></style>
    • <acronym id='9A21B44C83'></acronym>
      <center id='9A21B44C83'><center id='9A21B44C83'><tfoot id='9A21B44C83'></tfoot></center><abbr id='9A21B44C83'><dir id='9A21B44C83'><tfoot id='9A21B44C83'></tfoot><noframes id='9A21B44C83'>

    • <optgroup id='9A21B44C83'><strike id='9A21B44C83'><sup id='9A21B44C83'></sup></strike><code id='9A21B44C83'></code></optgroup>
        1. <b id='9A21B44C83'><label id='9A21B44C83'><select id='9A21B44C83'><dt id='9A21B44C83'><span id='9A21B44C83'></span></dt></select></label></b><u id='9A21B44C83'></u>
          <i id='9A21B44C83'><strike id='9A21B44C83'><tt id='9A21B44C83'><pre id='9A21B44C83'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:725
          Nasdaq
          Mario Tama/Getty Images

          Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

          The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

          advertisement

          The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          Readers discuss the intersection of pregnancy and addiction
          Readers discuss the intersection of pregnancy and addiction

          MollyFergusonforSTATFirstOpinionisSTAT’splatformforinteresting,illuminating,andmaybeevenprovocativea

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Deposition: Sackler embraced plan to conceal OxyContin’s strength

          RichardSacklerMollyFergusonforSTATThisstoryisacollaborationbetweenSTATandProPublica.InMay1997,theyea